Heron Therapeutics, Inc. (HRTX) income statement
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.27−0.01 (-3.26%)
Close on Nov 18, 2026Market cap $51.83MP/E –Yield –
Heron Therapeutics, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- 70.1%
- Operating margin
- -7.2%
- Net margin
- -22.5%
- Return on equity, FY2025
- 209.1%
Financial strength
- Current ratio
- 2.49
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 22.5%
Valuation
- P/E ratio
- –
- Price to sales
- 0.34
- Price to book
- 7.50
- Dividend yield
- –
See a number that looks wrong?